Evidence-based HMO care for prostate specific antigen testing.

Autor: Merenstein DJ; Department of Family Medicine, Georgetown University Medical Center, Washington, District of Columbia, USA., D'Amico FJ; Department of Mathematics and Computer Science, Duquesne University, Pittsburgh, Pennsylvania, USA.; University of Pittsburgh Medical Center-St. Margaret Hospital, Pittsburgh, Pennsylvania, USA., Vinker S; Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel.; Department of Family Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Petterson S; The Robert Graham Center for Policy Studies in Family Medicine and Primary Care, Washington, District of Columbia, USA., Lahad A; Department of Family Medicine, Hebrew University, Jerusalem, Israel.; Clalit Health Services, Jerusalem, Israel.
Jazyk: angličtina
Zdroj: The International journal of health planning and management [Int J Health Plann Manage] 2018 Jan; Vol. 33 (1), pp. 265-271. Date of Electronic Publication: 2016 Sep 20.
DOI: 10.1002/hpm.2388
Abstrakt: Background: There is pressure in the U.S. system to move away from fee-for-service models to a more pre-paid system, which may result in decreased costs, but the impact on evidence-based care is unclear. We examined a large pre-paid Health Maintenance Organizations (HMO) in Israel to see if evidence-based guidelines are followed for prostate specific antigen (PSA) testing.
Methods: A retrospective cohort of ambulatory visits from 2002 to 2011 of patients age >75 receiving care from Clalit Health Services was conducted. Historically reported U.S. cohorts were used for comparison. The main measure was the percent of patients who had at least one PSA after age 75.
Results: In each of the 10 years of follow-up, 22% of the yearly Israeli cohort, with no known malignancy or benign prostatic hyperplasia, had at least one PSA, while for the total 10 years, 30% of the men had at least one PSA. These rates are considerably lower than previously reported U.S. rates.
Conclusions: In a pre-paid system in which physicians have no incentive to order tests, they appear to order PSA tests at a lower rate than has been observed in the U.S. system. Additional quality of measures should continue to be examined as the U.S. shifts away from a fee-for-service model. Copyright © 2016 John Wiley & Sons, Ltd.
(Copyright © 2016 John Wiley & Sons, Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje